Financial interests in Big Pharma must now be recognized as conflicts of interest for any organization or individual who is offering opinions about national strategy, policy, or regulations regarding electronic cigarettes. Therefore, the authors of all scientific articles regarding electronic cigarettes must disclose any financial interests with pharmaceutical companies. Furthermore, organizations must also disclose any financial ties to Big Pharma when they offer recommendations regarding electronic cigarette policy.

The most interesting part of the study that I found was diacetyl can be found in all the sweet E-Juices. It was a known fact that diacetyl is present in most custard and creamy E-Juices as that is where the cream and butter flavoring comes from, but some of the fruity and sweet E-Juices and a lot of people in the community thought they were diacetyl free. Now granted Dr. Farsolinos was not transparent about the levels of diacetyl in each individual E-Juice so we can’t compare the fruit E-Juice diacetyl levels to that of the cream and custard E-Juices. However, I would assume that the E-Juices with creamy and custardy tones should have a higher concentration of diacetyl than that of the fruit and sweet flavors.

For those upset because they lost money on Super Bowl bets Sunday, I have good news for you. Next year, you can call a team of UC Riverside researchers for their premonitions about the Super Bowl outcomes before placing your bets. This research team has demonstrated themselves to be able to forecast the future, as they apparently are able to determine the conclusions of their research before even conducting the experiments.

Dr. Henningfield: "Dr. Henningfield is a Principal at, and derives most of his income from, Pinney Associates, a firm that currently provides to GSK on an exclusive basis consulting services regarding smoking-cessation products. His formal title is: Vice President, Research & Health Policy. Through his association with Pinney Associates, Dr. Henningfield advises GSK specifically on the development of nicotine-replacement therapies and treatments for tobacco dependence. Pinney Associates has received on average more than $2 million per year in revenue from pharmaceutical companies, more than half of which relates to smoking-cessation products. In addition, during the last decade, Dr. Henningfield has received grant support for research and writing from GSK on at least eight occasions. Dr. Henningfield is also a partner in a company that holds patents for a nicotine replacement-therapy product. He has estimated that, if thess patents are successfully licensed, they could be worth more than $1 million to him as a partner in that company. Thus, Dr. Henningfield has a financial interest in bringing about regulatory policies that will drive current smokers to use nicotine-replacement-therapy products."

LAST：Big vapor original aspire ce5 bdc clearomizer stock selling original aspire ce5 |NEXT：Hot sale protection ego ecig cloutank m3